Form 4: Kymera Therapeutics Director Sells Shares

Bruce Booth, a Director at Kymera Therapeutics, Inc., reported the sale of a significant number of common shares between June 23 and June 25, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Bruce Booth, a Director at Kymera Therapeutics, Inc., reported multiple transactions involving the sale of common stock from June 23 to June 25, 2026.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on December 11, 2025.
• The total number of shares sold across these transactions is substantial, with individual sales ranging from a few shares to over 100,000 shares on a single day.
• The sale prices varied, with transactions on June 23 occurring at a weighted average price of $99.98, and prices on June 25 ranging from $107.30 to $118.60.
• Following these transactions, Booth's beneficial ownership of Kymera Therapeutics common stock has decreased.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant volume of shares sold by a director, even though it was executed under a pre-planned 10b5-1 trading plan.

Negatives

• Director Bruce Booth has sold a significant portion of his holdings in Kymera Therapeutics, Inc. between June 23 and June 25, 2026.
• The total value of shares sold is in the millions of dollars, based on the reported prices and quantities.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5) through (18).
• The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
• The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.

Industry Context

StockSavvy.ai notes that insider selling, especially under a pre-arranged 10b5-1 plan, is common for executives and directors. While it can sometimes signal a lack of confidence, it often represents a pre-planned diversification or liquidity strategy, particularly for individuals with significant holdings tied to a single company's stock.

Stakeholder Impact

• Shareholders may view the significant sales by a director with concern, potentially impacting short-term stock sentiment.
• The sales are executed under a pre-defined plan, mitigating concerns about insider trading and suggesting a planned divestment rather than a reaction to adverse non-public information.

Key Dates

Recommendation

The filing reports routine insider sales under a 10b5-1 plan, which is a standard practice for portfolio management and does not inherently signal negative news about the company's future prospects. While significant selling can create short-term downward pressure, it does not provide enough information to warrant a strong buy or sell recommendation without further context on the company's performance and outlook.

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Stock Sale, Bruce Booth, Rule 10b5-1, Director Sale